Which thyroid cancers is Retsevmo (selpercatinib) indicated to treat in adults and adolescents aged 12 years and older?

Retsevmo (selpercatinib) is indicated as monotherapy in adults and adolescents aged 12 years and older with advanced RET fusion-positive thyroid cancer that is radioactive iodine-refractory (if radioactive iodine is appropriate), or advanced RET-mutant medullary thyroid cancer.